The Prodisc C Vivo received FDA approval for one-level indications in July.
The Prodisc C Vivo has been used internationally since 2009 and is one of the most frequently used total disc replacement products outside of the U.S., according to a Sept. 21 press release from Centinel Spine.
It utilizes Centinel Spine’s Prodisc Core technology, which has been used in total disc replacements for 30 years in over 225,000 implantations.
“We are pleased that leading spine surgeons, like Dr. Rasouli, are choosing to treat patients with Prodisc C Vivo. The anatomic endplate designs of the entire Prodisc cervical portfolio provide options for surgeons to choose the best disc for each patient according to their anatomy,” Steve Murray, Centinel Spine’s CEO, said in the release. “The Prodisc C Vivo implant is the newest option in Centinel Spine’s continued commitment to improving spine care.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
